Trial Profile
Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Brain metastases; Retinoblastoma
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2017 Status changed from recruiting to discontinued.
- 01 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 26 Mar 2014 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.